Literature DB >> 11455029

Diagnosis of bladder cancer with urinary cytology, immunocytology and DNA-image-cytometry.

B Planz1, C Synek, T Deix, A Böcking, M Marberger.   

Abstract

DNA-image-cytometry and antibodies directed against the Lewis X- and the 486p 3/12 antigen were applied to improve diagnostic accuracy of urinary cytology for the detection of bladder cancer. Cytology, immunocytology and DNA-image-cytometry were performed in spontaneously voided urine samples and barbotage bladder washings from 71 patients. The DNA content was determined using the CM-1 Cytometer according to the recommendation of the ESCAP Consensus Report on Standardization of DNA-image-cytometry (1995). For immunocytological examination we used the monoclonal anti Lewis X antibody P-12 and antibody 486p 3/12. All patients underwent subsequent cystoscopy and for any suspicious lesion biopsy or transurethral resection was done. Histological findings revealed 31 patients with transitional cell carcinomas of different stages and grades of malignancy. 40 patients had various benign diseases of the urinary bladder. Cytology yielded a sensitivity of 68% and a specificity of 100%. DNA aneuploidy was detected in 81% of cancer patients with a specificity of 100%. By combination of these two methods the overall sensitivity increased to 87%. Immunocytology with Lewis X and 486p 3/12 antibodies showed reactivity in 84% and 87% in combination with a specificity of 80% and 70%, respectively. By combining urinary cytology, immunocytology and/or DNA-image-cytometry the overall sensitivity increased to 94% with no change in specificity. DNA-image-cytometry should be used to evaluate particularly urothelial cells suspicious for malignancy in urinary specimens. Because of low specificity the monoclonal antibodies against Lewis X- and 486p 3/12 antigens are not helpful in screening for bladder cancer. Nevertheless, their high sensitivity may justify their use in case DNA image cytometry is not available and in the follow up of patients with transitional cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455029      PMCID: PMC4618007          DOI: 10.1155/2001/703731

Source DB:  PubMed          Journal:  Anal Cell Pathol        ISSN: 0921-8912            Impact factor:   2.916


  5 in total

Review 1.  Nephrogenic adenoma of the urinary bladder.

Authors:  Konstantinos Zougkas; Marinos Kalafatis; Panagiotis Kalafatis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

2.  Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.

Authors:  M G W Bol; J P A Baak; B van Diermen; S Buhr-Wildhagen; E A M Janssen; K H Kjellevold; A J Kruse; O Mestad; P Øgreid
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

3.  Nephrogenic adenoma of the urinary bladder.

Authors:  Konstantinos Zougkas; Marinos Kalafatis; Panagiotis Kalafatis
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.266

4.  The role of collecting bladder wash fluid before biopsy procedure to help the cytological diagnosis of residual tumor.

Authors:  Aydan Kiliçarslan; Nuran Süngü; Serdar Balci; Erdem Canda; Serkan Altinova; Gülnur Güler
Journal:  J Cytol       Date:  2015 Apr-Jun       Impact factor: 1.000

5.  Major differences in glycosylation and fucosyltransferase expression in low-grade versus high-grade bladder cancer cell lines.

Authors:  Bernadette Ezeabikwa; Nandini Mondal; Aristotelis Antonopoulos; Stuart M Haslam; Yasuyuki Matsumoto; Miguel Martin-Caraballo; Sylvain Lehoux; Msano Mandalasi; Ali Ishaque; Jamie Heimburg-Molinaro; Richard D Cummings; Anthony K Nyame
Journal:  Glycobiology       Date:  2021-12-18       Impact factor: 5.954

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.